-

Agilent Expands Cross-Vendor CDS Instrument Control

New software extends the company’s compatibility strategy

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the latest implementation of its mutual compatibility philosophy. Now, joint customers of Agilent Technologies and Thermo Fisher Scientific can choose a chromatography data system from either company—Agilent OpenLab CDS or Thermo Fisher Chromeleon—to control analytical instruments from both organizations.

The two companies recognize that reliable multivendor instrument control is critical to the successful operation of today’s analytical laboratories. Using a single data system increases lab productivity by saving substantial time managing software, training staff, and making it easier to meet the regulations that govern the lab.

“Agilent's multivendor control approach to laboratory informatics allows our customers to select the best hardware and software for their needs,” said John Sadler, vice president and general manager of Agilent's Software and Informatics Division. “That is why we invest in integrating third-party analytical instruments into our OpenLab software suite, in collaboration with other analytical instrument manufacturers. Our goal is to provide simple and complete support for our mutual customers.”

Agilent OpenLab CDS streamlines laboratory operations with a single, secure data system that combines chromatography and mass spectrometry into one software platform. OpenLab CDS is a multivendor platform controlling Agilent GC, LC, single quadrupole GC/MS, LC/MS instruments along with many other instrument vendors.

Thermo Fisher Scientific instrument families are the latest additions to OpenLab CDS multivendor control program. OpenLab CDS tools provide time-saving steps in the analysis, interpretation, and reporting workflows, enabling users to quickly identify key information, improve turnaround time, and ensure the highest level of data integrity.

“The lack of interoperability between different vendors’ instruments and software has traditionally presented a barrier to laboratories adopting the right solutions to meet the unique needs of their workflows,” said Matt Hazlewood, senior director, global enterprise chromatography data systems, at Thermo Fisher Scientific. “The renewal of our commitment with Agilent for mutual compatibility and third-party control of instruments ensures that customers will have continued access to our market-leading Chromeleon CDS software platform, meaning they can deploy the analytical solutions they need without compromising the flexibility or efficiency of their workflows.”

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Contacts

Naomi Goumillout
Agilent Technologies
+1.781.266.2819
naomi.goumillout@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Naomi Goumillout
Agilent Technologies
+1.781.266.2819
naomi.goumillout@agilent.com

More News From Agilent Technologies Inc.

Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a collaboration with OpenAI and Boston Consulting Group (BCG) to accelerate the deployment of artificial intelligence (AI) across the company’s products, operations, and customer workflows. “AI is a top priority, and this partnership reflects both our ambition and our execution commitment — to build the enduring capability, operating model, and capacity required to consistently deliver AI‑driven innovation...

Agilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the expanded use of PD-L1 IHC 22C3 pharmDx, Code GE006, for use on the Dako Omnis platform to aid in identifying patients in the United States with esophageal squamous cell carcinoma (ESCC)3, triple-negative breast cancer (TNBC)4, cervical cancer5, and gastric or gastroesophageal junction (GEJ) adenocarcinoma6, who may be eligible for treatment...

Agilent Introduces OpenLab Sync to Support Guided, Digital Execution in the Laboratory

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the introduction of OpenLab Sync, a new Lab Execution System (LES) that enables laboratories to digitally connect scientific workflows from method design through execution at the bench. OpenLab Sync extends Agilent’s OpenLab laboratory informatics portfolio beyond traditional data and sample management, enabling guided, standardized, and traceable execution of laboratory work in regulated environments. As...
Back to Newsroom